John W. Walsh Alpha-1 Home Infusion Act of 2025

Hozzl · 2025-04-22T16:03:40Z

Explore the details of House Bill 2343 John W. Walsh Alpha-1 Home Infusion Act of 2025 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

4/22/2025, 4:03 PM

Summary of Bill HR 2343

Bill 119 hr 2343, also known as the Alpha-1 Antitrypsin Deficiency Treatment Act, aims to amend title XVIII of the Social Security Act to include coverage and payment for treatment of Alpha-1 Antitrypsin Deficiency Disorder under part B of the Act. This genetic disorder affects the liver and lungs, leading to serious health complications.

The bill seeks to ensure that individuals with Alpha-1 Antitrypsin Deficiency Disorder have access to necessary treatments and medications through Medicare Part B. This would help alleviate financial burdens for patients and improve their quality of life.

In addition to providing coverage for treatment, the bill also includes provisions for research and education on Alpha-1 Antitrypsin Deficiency Disorder. This would help increase awareness of the disorder and improve diagnosis and treatment options for affected individuals. Overall, Bill 119 hr 2343 aims to address the needs of individuals with Alpha-1 Antitrypsin Deficiency Disorder by expanding Medicare coverage for treatment and supporting research and education efforts related to the disorder.

Congressional Summary of HR 2343

John W. Walsh Alpha-1 Home Infusion Act of 2025

This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 2343

Bill HR 2343 is currently in the status of Bill Introduced since March 25, 2025. Bill HR 2343 was introduced during Congress 119 and was introduced to the House on March 25, 2025. Bill HR 2343's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of March 25, 2025

Bipartisan Support of Bill HR 2343

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 2343

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 2343

To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes.